ICAM1 expression is induced by proinflammatory cytokines and associated with TLS formation in aggressive breast cancer subtypes

SL Figenschau, E Knutsen, I Urbarova, C Fenton… - Scientific reports, 2018 - nature.com
SL Figenschau, E Knutsen, I Urbarova, C Fenton, B Elston, M Perander, ES Mortensen…
Scientific reports, 2018nature.com
Intratumoral formation of tertiary lymphoid structures (TLS) within the tumor
microenvironment is considered to be a consequence of antigen challenge during anti-
tumor responses. Intracellular adhesion molecule 1 (ICAM1) has been implicated in a
variety of immune and inflammatory responses, in addition to associate with triple negative
breast cancer (TNBC). In this study, we detected TLS in the aggressive tumor phenotypes
TNBC, HER2+ and luminal B, whereas the TLS negative group contained solely tumors of …
Abstract
Intratumoral formation of tertiary lymphoid structures (TLS) within the tumor microenvironment is considered to be a consequence of antigen challenge during anti-tumor responses. Intracellular adhesion molecule 1 (ICAM1) has been implicated in a variety of immune and inflammatory responses, in addition to associate with triple negative breast cancer (TNBC). In this study, we detected TLS in the aggressive tumor phenotypes TNBC, HER2+ and luminal B, whereas the TLS negative group contained solely tumors of the luminal A subtype. We show that ICAM1 is exclusively expressed in TNBC and HER2 enriched subtypes known to be associated with inflammation and the formation of TLS. Furthermore, cell from normal mammary epithelium and breast cancer cell lines expressed ICAM1 upon stimulation with the proinflammatory cytokines TNFα, IL1β and IFNγ. ICAM1 overexpression was induced in MCF7, MDA-MB-468 and SK-BR-3 cells regardless of hormone receptor status. Taken together, our findings show that ICAM1 is expressed in aggressive subtypes of breast cancer and its expression is inducible by well-known proinflammatory cytokines. ICAM1 may be an attractive molecular target for TNBC, but further investigations elucidating the role of ICAM1 in targeted therapies have to take into consideration selective subtypes of breast cancer.
nature.com